Reuters logo
BRIEF-Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285
November 10, 2017 / 2:14 PM / 8 days ago

BRIEF-Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285

Nov 10 (Reuters) - Blueprint Medicines Corp

* Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes

* Blueprint Medicines Corp - ‍new cohort in second-line gist added to ongoing phase 1 trial​

* Blueprint Medicines Corp - ‍global, randomized phase 3 trial in third-line gist on track to initiate in first half 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below